Tag
Bhushan Akshikar
2 articles
GSK India Reports 10% PAT Growth, 34% EBITDA Margin
GSK India announced Q4 and FY26 results with 10% PAT growth to ₹1012 crore and 290 bps EBITDA margin expansion to 34%.
The Board recommended a final dividend of ₹57 per equity share for the year ended
GlaxoSmithKline Pharma Recommends Rs 57 Final Dividend
Board recommended final dividend of Rs 57 per share for FY26, subject to shareholder approval at AGM on 30th June 2026.
Approved audited standalone and consolidated financial results for Q4 and year e